Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/78667
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Should patients with systemic sclerosis-related pulmonary arterial hypertension be anticoagulated? |
Author: | Nikpour, M. Stevens, W. Proudman, S. Buchbinder, R. Prior, D. Zochling, J. Williams, T. Gabbay, E. Nandurkar, H. |
Citation: | Internal Medicine Journal, 2013; 43(5):599-603 |
Publisher: | Blackwell Publishing Asia |
Issue Date: | 2013 |
ISSN: | 1444-0903 1445-5994 |
Statement of Responsibility: | M. Nikpour, W. Stevens, S. M. Proudman, R. Buchbinder, D. Prior, J. Zochling, T. Williams, E. Gabbay and H. Nandurkar |
Abstract: | Pulmonary arterial hypertension (PAH) is a major cause of mortality in scleroderma and despite ‘advanced’ therapies confers a median survival of less than 5 years. Anticoagulation in systemic sclerosis-related PAH (SSc-PAH) is currently one of the most contentious issues in the management of patients with connective tissue disease. While some studies have shown a survival benefit with warfarin therapy in this disease, others have not. Accordingly, a state of clinical equipoise exists in relation to anticoagulation in SSc-PAH. With an over fivefold reduction in mortality demonstrated in some observational studies, the issue of anticoagulation in SSc-PAH demands resolution through a well-designed randomised controlled trial. |
Keywords: | scleroderma systemic sclerosis pulmonary arterial hypertension anticoagulation randomised controlled trial |
Rights: | © 2013 The Authors |
DOI: | 10.1111/imj.12111 |
Published version: | http://dx.doi.org/10.1111/imj.12111 |
Appears in Collections: | Aurora harvest 4 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.